OXiGENE

Oxigene gets $40M for pipeline work

Maureen Martino — Wed, 01 Oct 2008 12:49:14 -0400

Symphony Capital Partners is handing over $40 million to Oxigene to help the company advance its pipeline of vascular disrupting agent drug candidates for cancer and eye disease. Symphony will provide up to $25 million to Symphony ViDA newly-created company that will help accelerate OXi4503 and Zybrestat ophthalmology programs. Symphony will also invest $15 directly into Oxigene for general purposes, including oncology drug development. The group will put two members on Oxigene's board as part of the financing.

"The Symphony partnership significantly enhances OXiGENE's financial position, augments our drug development expertise, and helps accelerate the development and commercialization of our three clinical-stage VDA drug programs... Oxigene retains exclusive rights to all programs and gains further flexibility to partner its programs at a more advanced stage of development and from a position of greater strength. Furthermore, the collaboration terms transfer the development risk of the OXi4503 and ZYBRESTAT for ophthalmology programs to Symphony, as our purchase option for the Symphony ViDA assets represents a right but not an obligation to reacquire the programs," said John Kollins, COO of Oxigene.

- see Oxigene's release

Related Articles:
Oxigene inks $40M capital deal
Oxigene touts cancer data (Oct. 2005)

ALSO NOTED: Ardana looks to sale or merger; Oxigene inks $40M capital deal; and much more...

Wed, 20 Feb 2008 06:59:50 -0500

> Edinburgh-based Ardana's CEO, says the biotech is looking for a sale or merger. Report

> Oxigene has inked a deal with Kingsbridge Capital for $40 million in capital over three years. Release

> Oxford Biomedica has completed a late-stage trial of its cancer therapy TroVax, triggering a €10 million milestone payment. Release

> Scientists in the U.K. have identified a molecule that they say plays a critical role in the development of allergies. Report

> A growing demand for new biotech and lab space is forcing up rents in the Washington DC area as vacancies decline. Report

> There's a new target for drug developers focused on multiple sclerosis--and a pair of approved drugs that may already work against the disease. Report

> Some biotechs are eager for the FDA approval of biogeneric drugs. Report

> A new survey has concluded that specialists feel Medicare's new anemia drug payment limits are hurting cancer patients. Report

> Various agencies are taking aim at pro quo deals between brand-name drug makers and generics firms. Report

> Amgen harshly rejected a royalty offer from Roche, which wants to sell an anemia drug that would compete against Amgen's signature blockbusters. Report

And Finally... A 20-year effort to find a microbicide that protects women from HIV ended in another bitter setback for researchers who reported that a late-stage trial of a new gel has failed. Report

ALSO NOTED: FDA to speed up generic approval; Genfit starts Phase II trials; and much more...

Fri, 05 Oct 2007 06:59:50 -0400

Could the steady trickle of generics approvals out of the FDA suddenly become a rapid stream? The agency is touting an initiative, called Generic Initiative for Value and Efficiency (GIVE), to speed up generic approvals. The FDA says it will hire more staff to review generic apps, use computers to streamline the process, and "when possible," divert resources from other departments to the effort. Report

> France-based Genfit has launched two Phase II clinical trials for its GFT505, an experimental treatment for type IIb dyslipidemia and atherogenic dyslipidemia in pre-diabetic patients with abdominal obesity. Release

> OXiGENE announced Interim results from a Phase Ib study of zybrestat-bevacizumab, a treatment for advanced solid tumors. Release

> Novartis got the EU's approval to sell its new osteoporosis drug Aclasta, known in the U.S. as Reclast. But on the flip side, Canadian regulators pulled the pain pill Prexige because of the same liver-damage fears that brought it down in Australia in August. Report

And Finally... University of Florida doctors treated their first patient enrolled in a new study designed to test whether injecting stem cells into the heart helps restore blood flow to the organ by prompting new blood vessels to grow. Release